531752 — Biogen Pharmachem Industries Income Statement
0.000.00%
Last trade - 00:00- IN₹580.82m
- IN₹577.59m
Annual income statement for Biogen Pharmachem Industries, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 16.2 | 24.7 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 1.42 | 4.59 | — | — |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.17 | 32.3 | 24.9 | 4.57 | 4.51 |
| Operating Profit | -1.17 | -16 | -0.154 | -4.57 | -4.51 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.17 | -16 | -0.086 | 4.55 | 19.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.17 | -16 | -0.086 | 4.55 | 19.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.17 | -16 | -0.086 | 4.55 | 19.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.17 | -16 | -0.086 | 4.55 | 19.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.025 | -0 | 0.007 | 0.03 |